Memorial Sloan Kettering to Present Clinical Data from The ARETHA-1 Trial of SynDevRx’s Evexomostat in mTNBC at SABCS
Safety Run-in Cohort Results Show Anti-tumor Activity Plus Systemic Metabolic Improvements with Evexomostat Plus Eribulin in Late-line Metastatic TNBC Patients NEW YORK, NY, UNITED STATES, December 2, 2025 /EINPresswire.com/ -- Memorial Sloan Kettering …